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Abstract
Prepulse inhibition (PPI) is a compelling endophenotype (biological markers) for mental disorders including schizophrenia.
In a previous study, we identified Fabp7, a fatty acid binding protein 7 as one of the genes controlling PPI in mice and
showed that this gene was associated with schizophrenia. We also demonstrated that disrupting Fabp7 dampened
hippocampal neurogenesis. In this study, we examined a link between neurogenesis and PPI using different animal models
and exploring the possibility of postnatal manipulation of neurogenesis affecting PPI, since gene-deficient mice show
biological disturbances from prenatal stages. In parallel, we tested the potential for dietary polyunsaturated fatty acids
(PUFAs), arachidonic acid (ARA) and/or docosahexaenoic acid (DHA), to promote neurogenesis and improve PPI. PUFAs are
ligands for Fabp members and are abundantly expressed in neural stem/progenitor cells in the hippocampus. Our results
are: (1) an independent model animal, Pax6 (+/2) rats, exhibited PPI deficits along with impaired postnatal neurogenesis; (2)
methylazoxymethanol acetate (an anti-proliferative drug) elicited decreased neurogenesis even in postnatal period, and PPI
defects in young adult rats (10 weeks) when the drug was given at the juvenile stage (4–5 weeks); (3) administering ARA for
4 weeks after birth promoted neurogenesis in wild type rats; (4) raising Pax6 (+/2) pups on an ARA-containing diet
enhanced neurogenesis and partially improved PPI in adult animals. These results suggest the potential benefit of ARA in
ameliorating PPI deficits relevant to psychiatric disorders and suggest that the effect may be correlated with augmented
postnatal neurogenesis.
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Introduction
The etiologies of psychiatric illnesses are largely unknown.
Recently, biological traits relevant to psychiatric illnesses called
‘‘endophenotypes’’ have gained attention. Among them, deficits in
prepulse inhibition (PPI) have been well documented across
mental disorders including schizophrenia [1,2]. PPI is the normal
suppression of a startle response when a low intensity stimulus
eliciting little or no behavioral response, immediately precedes an
unexpected stronger startling stimulus [1]. Biologically, PPI is
deemed to be a reflection of sensory motor gating functions within
the central nervous system. The experimental advantage of PPI is
that it is evaluable in animals. It is known that specific brain
regions, including the hippocampus, cortex, amygdala and nucleus
accumbens, form a circuit for PPI [3] (Figure S1), with
hippocampal involvement being well studied. For instance,
Weinberger and his colleagues reported that when rats received
ventral hippocampal ablation during the early postnatal period,
they exhibited PPI defects at the later adult stage [4].
In our recent study, we identified Fabp7, that encodes a brain-
type fatty acid binding protein (also known as brain lipid binding
protein; BLBP) as a gene responsible for PPI in mice and showed
that human FABP7 is a susceptibility gene for schizophrenia [5].
Fabp7-deficient mice did not show gross anatomical brain
abnormalities, but interestingly, neurogenesis is impaired in the
hippocampus. A similar biological cascade of ‘‘decreased neuro-
genesis’’ ‘‘impaired PPI’’ and ‘‘genetic association with schizo-
phrenia’’ has been reported for Npas3 [6–8] and Neuregulin1 [9–11].
Here, we further address the question of whether decreased
neurogenesis not only in the fetal (this is probably true in gene
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5085ablated animals) but also the postnatal period may serve as a
determinant for PPI deficits. Since examining gene knockout mice
would not be able to distinguish these ‘critical period’ issues, we
utilized both genetic and pharmacological approaches in the
analyses of Pax6(+/2) rats (for the former approach) and normal
rates treated with the anti-proliferative drug, methylazoxymetha-
nol acetate (MAM) after birth (for the latter one). In parallel, we
also examined whether the dietary administration of polyunsatu-
rated fatty acids (PUFAs) such as docosahexaenoic acid (DHA)
and arachidonic acid (ARA) enhance neurogenesis in the rat
hippocampus and elicit improved PPI. The ultimate hope is for
developing preventive measures for mental disorders. In this study,
we analyzed rats as experimental animals, because our study
contained nutritional (varying lipid-containing feed) and to some
degree toxicological issues where the use of rats is legitimate
(http://www.ich.org/cache/compo/276-254-1.html). We found
that disturbed postnatal neurogenesis led to impaired PPI. In
contrast, ARA specifically promoted hippocampal neurogenesis
and mitigated PPI defects seen in Pax6(+/2) rats that display both
debilitated neurogenesis and PPI.
Materials and Methods
Animals
Wild-type (from CLEA JAPAN, Tokyo, Japan) and Pax6 (+/2)
(both on a Sprague-Dawley background) rats were maintained at
Tohoku University, Sendai, Japan and Mitsubishi Kagaku
Institute of Life Sciences, MITILS, Tokyo, Japan. All animal
experiments were carried out in accordance with the National
Institute of Health guidelines for the care and use of laboratory
animals, and were approved by The Committee for Animal
Experiments in the aforementioned organizations.
PPI measurements
Rats were tested in a startle chamber (SR-lab System, San
Diego Instruments, San Diego, CA) positioned within a sound-
proof cabinet in a sound-attenuating room according to standard
methodology [12]. A constant background white noise of 65 dB
was presented throughout the test. To measure prepulse inhibition
(PPI), rats were presented with a 68, 71 or 77 dB prepulse (pp68,
pp71 or pp77 for 20 ms) followed by a 105 or 120 dB pulse (for
40 ms in length) 100 ms later. The percentage PPI of the startle
response was calculated using the following formula: 100-[(SRPP/
SR)6100], where SR denotes the startle response to the pulse
stimulus, and SRPP denotes the startle response to the pulse with
prepulse stimulus.
MAM treatment and subsequent analyses
Four-week old wild-type rats were intraperitoneally injected
with MAM (0, 5, 7, 10 or 15 mg/kg) once a day for 1 week. For 5-
bromo-2-deoxyuridine (BrdU) analysis (see below), MAM treated
5 and 10-week old rats were given a single BrdU injection and
sacrificed 2 hours later. For behavioral analyses, the MAM treated
rats were handled for 1 week, and then subjected to PPI tests.
PUFA diets
We prepared 3 different diets by altering the fatty acid
composition of AIN-76A: control, ARA(+), DHA(+) and ARA(+)-
DHA(+) diets (Table 1). Dietary foods with ARA or DHA were
stored at 4uC and shaded from the light to prevent oxidation and
denaturation. In addition, they were not treated with gamma rays
or autoclave sterilization. Wild-type and Pax6(+/2) rats were fed
from postnatal day 2 (P2) with DHA or ARA-triglyceride
supplementation until they were used for various analyses.
Immunohistochemistry
For the analyses of expression markers related to cell
proliferation, at least five rats at P30 were examined. Rats were
deeply anesthetized with sodium pentobarbital and then transcar-
dially perfused with 4% paraformaldehyde and 0.5% picric acid in
0.01 M phosphate-buffered saline (PBS). The brains were
removed and further immersion-fixed in the same fixative at
4uC for 2 hours. Coronal sections of 14 mm thickness were
prepared using a cryostat (CM3050, Leica, Germany). The
sections were washed with Tris-buffered saline containing Tween
20 (TBST; pH 7.4). For immunostaining, the cryostat sections
were incubated at 4uC for 18 hours with primary antibodies. For
detection of the antigen localization, sections were incubated at
4uC for 2 hours with appropriate secondary antibodies. Informa-
tion on the primary and secondary antibodies and other reagents
is listed in Table S1. Fluorescent signals were detected using
a confocal laser-scanning microscope (LSM5 Pascal, Zeiss,
Germany) or a fluorescent microscope (Axioplan-2, Zeiss,
Germany).
Table 1. Fatty acid composition of the modified AIN-76A diets used in this experiment.
Fatty acids PUFA Diets
Abbreviated notation Conventional name Control (%) ARA(+) (%) DHA(+) (%) ARA(+)DHA(+)( % )
16:0 Palmitic acid 11.5 11.3 11.6 11.6
18:0 Stearic acid 2.2 2.9 2.4 2.9
18:1 n-9 Oleic acid 28.8 26.8 28.6 26.6
18:2 n-6 Linoleic acid 54.7 50.3 50.4 46.1
18:3 n-3 alpha-Linolenic acid 0.9 0.9 0.9 0.8
20:3 n-6 Dihomo-gamma-linolenic acid 0.0 0.3 0.0 0.3
20:4 n-6 Arachidonic acid (ARA) 0.0 4.0 0.0 4.0
22:6 n-3 Docosahexaenoic acid (DHA) 0.0 0.0 4.0 4.0
Others 1.9 3.5 2.1 3.7
Total (%) 100.0 100.0 100.0 100.0
doi:10.1371/journal.pone.0005085.t001
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P30 rats fed on either control or ARA(+) or DHA(+)o r
ARA(+)DHA(+) diets received intraperitoneal injections of BrdU
(Sigma, St. Louis, MO) at 50 mg/kg body weight (10 mg/ml
stock, dissolved in 0.9% saline), 3 times a day and were sacrificed
after 1 day. Fourteen mm frozen sections were boiled in 0.01 M
citric acid and incubated in 2 N HCl for 10 min at 37uC, and
washed in 0.01 M PBS. For quantification analysis, sampling of
BrdU-positive cells was done throughout the dentate gyrus (DG) in
its rostrocaudal extension. Three consecutive sections (14 mm
each) out of a total of 18 sections were used for counting, and the
total number of positives was obtained by multiplying the value by
6 [13].
Results
PPI deficits in Pax6(+/2) rats
We examined Small eye rats (rSey
2) that have a mutation in the
transcription factor gene Pax6 which controls neurodevelopment
[14]. This animal model displays decreased hippocampal neuro-
genesis without any gross structural abnormalities in the brain
[13]. TodeterminewhetherheterozygousPax6mutant[Pax6(+/2)]
ratshavePPIdefects(thehomozygousmutantionislethal),wescored
PPI with acoustic stimuli (105 dB startle sound) at different
postnatal stages (Figure 1A–1C). PPI levels were significantly
lowered with 68 and 71 dB prepulse stimuli (P=0.0038 and
P=0.0468, respectively; Figure 1B) at 12–20 weeks, and with
71 dB prepulse sound (P=0.0098; Figure 1C) at 36–40 weeks in
Pax6(+/2) rats, compared to wild-type rats. Decreased PPI was
also observed when a pulse (startle sound) was set at 120 dB
(data not shown). Interestingly, defects in PPI were not observed
in juvenile rats (6 weeks; Figure 1A). This may correspond to
the fact that schizophrenia, a typical mental illness that shows
decreased PPI, develops after adolescence. The magnitude of
the startle response itself was not significantly different between
the wild type and Pax6(+/2) rats (Figure S2). Other behaviors
were normal in Pax6(+/2) rats, except for rearing activity and
the light-dark choice test (data not shown).
Postnatal MAM treatment provokes reduction in
neurogenesis and deficits in PPI
To explore the causative relationship between postnatal
neurogenesis and PPI outcome in-depth, we used the drug
MAM, a known attenuator of neurogenesis [15]. We administered
the MAM to juvenile wild-type rats for 1 week (from at 4 to 5
weeks), and examined neurogenesis (at 5 and 10 weeks) and scored
PPI (at 10 weeks) (Figure 2A and Figure S3A). The MAM-treated
rats showed a transient decrease (63% of the control value) in
hippocampal neurogenesis at 5 weeks (Figure 2B), then recovered
neurogenesis to control levels by 10 weeks (Figure 2B). But
interestingly, they displayed impaired PPI (at pulse levels of both
105 dB and 120 dB) at 10 weeks (Figure 2C and Figure S3A, S3B,
S3C). We could not detect any differences in general activity
measured by the open-field test at 10 weeks (data not shown).
These results show that disturbances of postnatal neurogenesis, at
least during the juvenile period, could evoke PPI deficits later
in adulthood, without affecting locomotor activity. In addition, this
is the first study demonstrating that PPI deficits can be induced
by MAM treatments not only at fetal [16] but also at postnatal
stages.
Administration of arachidonic acid increases postnatal
neurogenesis in the rat hippocampus
We thought that if we could foster hippocampal neurogenesis
using dietary supplements, we could ameliorate PPI deficits, a
biological marker relevant to mental disorders. We tested PUFAs
because: (1) Fabp7 and another Fabp member Fabp5, can bind
PUFAs [17,18], and are abundantly expressed in neural stem/
progenitor cells from fetal [19,20] to adult stages (Figure S4A,
S4B, S4C, S4D, S4E, S4F); and (2) Fabp7 is required for
proliferation of neuroepithelial cells [19]. For the PUFAs, we chose
the typical n-3 and n-6 lipids, DHA and ARA, respectively, and
prepared dietary pellets containing these PUFAs (Table 1). PUFAs
can be absorbed into the digestive organs and blood stream, and
subsequently secreted into breast milk [21,22]. When rat pups suck
breast milk from their mothers treated with PUFAs, it is expected
that PUFAs will be transmitted to body organs including the brain
Figure 1. Impaired PPI in Pax6(+/2) rats. Wild type and Pax6(+/2) rats were tested for acoustic prepulse inhibition (PPI) of an acoustic startle
response. Each rat was subjected to trials of different prepulse stimuli (pp) (68, 71, or 77 dB) with startle stimuli of 105 dB. (A) At 6 weeks, scores of
PPI were not different between the wild type and Pax6(+/2) rats. n.s., not significant. (B) At 12–20 weeks, Pax6(+/2) rats showed a decrease in PPI at
pp68 and pp71 compared with wild type rats. (C) Similar defects in PPI of Pax6(+/2) were also observed in rats aged over 36 weeks at pp71. Student
t-test was used and error bars show mean6SE.
doi:10.1371/journal.pone.0005085.g001
Fatty Acid, Neurogenesis, PPI
PLoS ONE | www.plosone.org 3 April 2009 | Volume 4 | Issue 4 | e5085via the blood-brain barrier of the pups. Data presented below
confirms that this occurred (see section below).
Rat pups from P2 and older and their mothers were fed with
control, ARA(+), DHA(+), ARA(+)DHA(+) diets for 4 weeks
(Figure 3A). We first measured the ratio of DHA and ARA in the
hippocampus of the treated rat pups at P31, and confirmed that
the ratio of ARA/DHA increased or decreased according to the
administration of ARA or DHA, respectively (Text S1, Figure
S5A, S5B). Next, the PUFA-treated rats were intraperitoneally
injected with BrdU three times at day 30 (P30) and sacrificed one
day after BrdU injections (at P31) (Figure 3A). We compared the
total number of BrdU+ cells in the dentate gyrus (DG) of the
control diet-, ARA(+) diet-, DHA(+) diet-, ARA(+)DHA(+) diet-
treated rats. A 32 percent increase in the total number of BrdU-
labeled cells was observed in ARA(+) diet-treated rats compared to
control diet-treated rats (Figure 3B and 3C), whereas there were
no significant differences between the control diet and DHA(+)
diet- and between control diet and ARA(+)DHA(+) diet-treated
rats (Figure 3C), although a trend of slight increase was seen in the
DHA(+) diet- and to lesser extent ARA(+)DHA(+) diet-treated rats.
We further investigated whether neural stem/progenitor cells in
the DG were increased in ARA(+) diet-treated rats. Interestingly,
GFAP (glial fibrillary associated protein) positive cells were slightly
increased (data not shown), while PSA-NCAM (polysialylated
neural cell adhesion molecule) positive cells were dramatically
increased (Figures S6A, S6B) at P31. Both GFAP and PSA-NCAM
are markers for hippocampal neural progenitor cells, with the
former being the earlier stage [23,24]. Significantly, we observed
an elevated number of mossy fibers that expressed PSA-NCAM
(data not shown). These data clearly indicate that the number of
proliferating progenitors and subsequent newly-born neurons is
considerably increased in the hippocampal subgranular zone
(SGZ) of ARA(+) diet-treated rats. We confirmed that most of
these proliferating cells went on to differentiate into neurons at 1
(Figure S7A, S7B, S7C, S7D) and 4 (data not shown) weeks later.
Administration of arachidonic acid augments
neurogenesisandamelioratesPPIdefectsinPax6(+/2)rats
Since dietary ARA improved neurogenesis in normal rats, we
embarked on a study to see whether ARA-treatments could restore
defective neurogeneis (an approximately 30% decrease) in Pax6(+/
2) rats [13]. Wild type and Pax6(+/2) rat pups were raised on
diets either containing or lacking ARA from day P2 to P31
(Figure 4A). When the ARA(+) diet was given to Pax6(+/2) rats,
neurogenesis was increased by 33% at P31 compared to those fed
with control diet (Figure 4B).
These results prompted us to see whether impaired PPI in
Pax6(+/2) rats could be also reinstated by ARA-treatment,
providing a potential therapeutic intervention. The reduced PPI
seeninPax6(+/2)ratswaspartiallyrecoveredwithanARA(+)dietat
15 weeks, compared to Pax6(+/2) rats fed with a control diet
(Figure4C)[alsonotethattherewerenosignificantdifferencesofPPI
between wild-type rats with ARA(+) diet and Pax6 mutants with
ARA(+) diet] (for the results of PPI at pp 71 dB, see Figure S8).
Discussion
Although PPI has been most frequently studied in schizophre-
nia, impairments have also been observed in patients with
neuropsychiatric disorders including bipolar disorder, autism and
Figure 2. Decreased neurogenesis and impaired PPI in MAM-treated wild-type rats. (A), Experimental design for MAM treatment, BrdU
assay and behavioral analyses in wild-type rats. (B), The number of BrdU-positive cells was decreased to 63% in the DG of MAM (10 mg/kg)-treated
wild-type rats at 5 week, but did not differ between the two groups at 10 weeks of age. n.s., not significant. (C), PPI defects were observed at pp68
with a startle stimuli of 105 dB at 10 weeks in MAM-treated rats. Student t-test (B) or Fisher’s PLSD test (C) was performed and error bars show
mean6SE.
doi:10.1371/journal.pone.0005085.g002
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PLoS ONE | www.plosone.org 4 April 2009 | Volume 4 | Issue 4 | e5085Figure 4. Effects of ARA(+) diets on neurogenesis and PPI in Pax6(+/2) rats. (A), Experimental design of the analyses. (B), The number of
BrdU-positive cells in the DG of ARA(+) diet-treated Pax6(+/2) rats was 33% higher than in control diet-treated Pax6(+/2) rats. Student t-test was
performed and error bars show mean6SE. (C), ARA restored PPI defects in Pax6(+/2) rats to a non-significantly different level compared to wild-type
rats (the second column vs. the forth column), at pp68 with a startle stimuli of 105 dB. Scheffe’s F test was performed and error bars show mean6SE.
n.s., not significant.
doi:10.1371/journal.pone.0005085.g004
Figure 3. Effects on cell proliferation in the DG of ARA(+) and/or DHA(+) diet-treated wild-type rats. (A), Experimental design of the BrdU
assay in PUFA (polyunsaturated fatty acid)-treated wild-type rats. Rat pups and their mothers were fed with varying PUFA-containing food from P2 to
P31. They were sacrificed at 1 day after intraperitoneal BrdU injections. (B), The number of BrdU-positive cells was increased in the DG of ARA(+) diet-
treated wild-type rats (lower panel) compared to those of control diet-treated rats (upper panel) at 1 day after BrdU injections. (C), The number of
BrdU-positive cells in the DG of ARA(+) diet-treated wild-type rats was 32% higher than control diet-treated rats, while DHA(+) and ARA(+)DHA(+)
diet-treated wild-type rats showed non-significant increase (+9% and +5%, respectively).
doi:10.1371/journal.pone.0005085.g003
Fatty Acid, Neurogenesis, PPI
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shared neural dysfunction across the current diagnostic categories
of mental disorders. Therefore, in this study, we targeted PPI as a
behavioral phenotype that is highly relevant to psychiatric illnesses
and may constitute an important aspect of the pathophysiology of
these diseases.
In this study, we have shown that postnatal neurogenesis can be
impaired by an environmental milieu, MAM-treatments, in
addition to gene disruptions (Pax6 in the current study) in rats.
In addition, we reveal for the first time that even postnatal MAM
administration can induce PPI deficits. It is already known that the
MAM-induced decrease in fetal neurogenesis can cause PPI
deficits [16]. The current findings also suggest that once postnatal
neurogenesis is impaired, at the developmental period equivalent
to adolescence in humans even if neurogenesis recovers later in
life, the susceptibility for PPI deficits remains. This may mean that
a ‘critical period’ for the formation of neural circuits underlying
PPI spans at least 4–5 weeks in rats. The 4–5 week-old rats show
salient neurogenesis [13]. However, because we did not examine
other developmental periods for MAM-treatments, we recognize
the need for further studies to determine the chronological
relationship between impaired neurogenesis and reduced PPI.
It is noteworthy that the administration of ARA successfully and
dramatically increased neurogenesis not only in wild-type but also
Pax6(+/2) rats. It is known that prostaglandin E2 (PGE2) plays an
important role in neurogenesis [26], stimulates CB2, a receptor for
endocannabinoids and promotes mouse neural stem cell prolifer-
ation [27]. Both PGE2 and endocannabinoids are metabolites of
ARA. It is also possible that ARA itself augments proliferation of
neural progenitor cells. ARA could be transmitted from Fabps to
nuclear receptor proteins [17], thereby indirectly controlling the
transcription of genes related to cell proliferation. This scenario is
analogous to that where retinoic acid (a metabolite of vitamin A) is
transmitted from a cellular retinoic acid binding protein and
Fabp5 to nuclear receptors RAR and PPARb/d, respectively [28].
We also speculate from our current study that the effect of DHA
albeit small, may be caused by promoting differentiation and
prevention of apoptosis, rather than by increasing cell proliferation
[Figures S7B, S7D] [29]. The precise mechanisms for the role of
PUFAs in fostering neurogenesis, however, warrants further
studies.
Treating the Pax6(+/2) rats with ARA for 15 weeks from birth,
we were able to alleviate their PPI defects. Because this was the
first attempt to evaluate the effects of ARA on PPI, we
administered ARA long term to obtain an unequivocal and
maximum outcome. There are several possibilities of how ARA
can prevent or restore PPI defects in our model rodents. One
explanation is that ARA affects postnatal neurogenesis in several
brain regions including the hippocampus, and eventually leads to
modifications of the neural circuitry of PPI [see Figure S1 and
Table S2]. It may not be excluded another explanation, for
example, that ARA can directly influence the fluidity of neuronal
membranes, thereby regulating neuronal transmission [17,30]
because ARA was continuously administered until scoring PPI. In
this case, we may have to consider the roles of Fabp3 also. Fabp3 is
expressed in mature neurons in the dentate gyrus (our unpublished
results) and reported to have a substantial affinity to ARA [31].
On one hand, the recovery of PPI was not complete in the
Pax6(+/2) rats. It is likely that the multiple neuro-functional
disturbances caused by the gene defect cannot be fully compen-
sated for by postnatal nutritional interventions. In contrast to
Mendelian disorders that are usually caused by single gene defects
and often manifest with serious physical and/or intellectual
abnormalities without effective cures, predisposition to functional
psychiatric illnesses is generally associated with multiple suscep-
tibility gene variants with small to modest effects [32]. Therefore,
we believe that the improved PPI demonstrated in this study (albeit
not complete in gene-disrupted rats), could be meaningful when
developing risk-reducing measures for mental disorders.
There are numerous clinical studies reporting symptomatic
improvements of schizophrenia and other mental illnesses
including mood disorders when PUFAs are given in combination
with psychotropic drugs, although PUFAs alone are not sufficient
as therapeutic agents [33–36]. Such PUFAs are exclusively n-3
fatty acids like EPA (eicosapenteanoic acid) and DHA. The
currently observed beneficial effects of ARA may due to the period
of administration, i.e. an early postnatal stage, which is different
from those examined in human studies. Interestingly it has been
reported that patients with schizophrenia show a reduced niacin
(vitamin B3) skin flush response, although there is wide inter-
individual variation [37]. In this test, varying concentrations of
niacin are applied to forearm skin and the flush response is rated
[38]. A decreased flush response is deemed to be a peripheral
marker of disturbed lipid-ARA pathways [39].
There are two large epidemiological studies demonstrating that
when pregnant mothers suffered from famine, the risk of their
offspring developing schizophrenia increased to two fold [40,41].
As a potential mechanism, Heijman et al. recently reported that
individuals who were prenatally exposed to famine in Holland
had, 6 decades later, less DNA methylation of an imprinted gene
compared with their unexposed, same-sex siblings [42]. Therefore,
relationship between ARA treatments (and their timing) and
epigenetic changes would make a compelling topic for future
research. Although multiple nutrients are needed for healthy brain
development and maintenance, our current results suggest that an
adequate maternal dietary intake of ARA may be especially
important for reducing the vulnerability of brains to mental
illnesses.
Dietary ARA is a PUFA that can be transmitted directly into the
brain via the blood-brain barrier and occurs naturally in
nourishing foods such as meat, eggs, fish and seaweed. ARA
would therefore appear to be a beneficial molecule for promoting
neurogenesis and PPI integrity in a safer way than many artificial
compounds. We hope that future studies address the possibility
that PUFAs given to lactating mothers (and to young children up
to puberty) may reduce the burden of psychiatric diseases
including schizophrenia [43,44]. These studies should clarify the
untested issues including the optimal ratio of n-3 and n-6, the total
dosage of PUFAs, the time of intervention and period of
administration.
Supporting Information
Figure S1 Schematic model of neural substrates regulating
acoustic startle and PPI. The neural circuit is based on reference
[43]. In the hippocampus (HPC) neurogenesis occurs throughout
life (but prominent in early postnatal period). The nucleus
accumbens (NAC) is a pivotal anatomical substrate in the circuit,
and there is a report demonstrating that postnatal neurogenesis
occurs also in this brain region until P7 [47]. The abbreviations
are: Aud, auditory cortex; BLA, basolateral amygdala; Coch,
cochlea; IC, inferior colliculus; MPFC, medial prefrontal cortex;
MS, medial septal nucleus; NAC, nucleus accumbens; HPC,
hippocampus; MD, mediodorsal thalamus; PnC, nucleus reticu-
laris pontis caudalis; PPTg, pedunculopontine nucleus; SC,
superior colliculus; VP, ventral pallidum; VTA, ventral tegmental
area.
Found at: doi:10.1371/journal.pone.0005085.s001 (0.84 MB TIF)
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amplitude in response to 65, 68, 71, 77, 80, 83, 89, or 95 dB
stimuli was measured in both the wild-type and Pax6(+/2) rats.
There were no differences between the two groups of rats.
Student t-test was performed and error bars show mean6SE.
n.s., not significant between the two groups of rats at each startle
stimulus.
Found at: doi:10.1371/journal.pone.0005085.s002 (1.31 MB TIF)
Figure S3 PPI in MAM-treated wild type rats. (A) Experimental
design for MAM treatments and PPI test in wild-type rats. (B, C)
PPI defects were observed at pp71 dB with a startle sound of
105 dB, and at pp68 and 71 with startle stimulus of 120 dB at 10
week in the MAM-treated rats. Fisher’s PLSD test was performed
and error bars show mean6SE.
Found at: doi:10.1371/journal.pone.0005085.s003 (1.40 MB TIF)
Figure S4 Expression patterns of Fabp7 and Fabp5 in the DG of
wild-type rats. Previous studies have reported that Fabp7 is
expressed in the subgranular zone (SGZ) of the hippocampal DG,
and is co-expressed with GFAP [48], a marker for astrocytes and
neural stem/early progenitor cells. It has also been shown that
Fabp5, another member of the fatty acid binding protein family, is
expressed in the hippocampus [20]. However, to date no detailed
information has been available on cell types that are positive for
Fabp7 and Fabp5 during hippocampal neurogenesis. In this study,
we revealed for the first time the cell types that express Fabp7 and
Fabp5 in the hippocampus by using immunostaining methodol-
ogy. (A, B) Many Fabp7 positive and Fabp5 positive cells are
observed in the subgranular zone (SGZ) and hilus of hippocampus
at postnatal day 28 (P28). A much smaller number of Fabp7 and
Fabp5 positive cells were detected in the hilus and the molecular
layer, with very few cells in the granule cell layer (GCL). Fabp7
and Fabp5 positive cells were highly proliferative; all cells
incorporated BrdU within 1 day (data not shown). The pattern
and morphology of Fabp7 positive cells differed slightly from
Fabp5 positive cells, in that Fabp7 positive cells had long, thin
projections and were present as individual cells (A inset), while
Fabp5 positive cells formed clusters (B inset). These findings
suggest that Fabp7 positive cells are slightly more primitive neural
progenitor cells compared to Fabp5 positive cells. (C–E) We
performed double staining analyses using various markers for
neural stem/progenitor cells, neurons and astrocytes. (C, E) Many
Fabp7 positive cells (65.0%) co-expressed an early progenitor
marker GFAP, and the majority of Fabp7/GFAP double positive
cells exhibited processes that were oriented radially into the GCL
of the DG. Fabp7 positive cells also expressed a neural stem cell
marker nestin. About a third of Fabp7 positive cells (40.4%) co-
expressed a late progenitor marker, PSA-NCAM. However,
Fabp7 positive cells rarely expressed the granule cell marker
calbindin D-28k (4.8%). In addition, the ratio of Fabp7 positive
cells to the total of BrdU positive cells was 100% in the DG of
hippocampus. (D, E), A smaller proportion of Fabp5 positive cells
(38.8%) co-expressed GFAP, and the majority of Fabp5 positive
cells were distributed as clusters, in contrast to Fabp7 positive cells
(A, B). Moreover, many of the Fabp5 positive cells co-expressed
PSA-NCAM (59.7%), and some of Fabp5 positive cells co-
expressed nestin. A slightly higher proportion of Fabp5 positive
cells expressed calbindin D-28k (15.4%) than Fabp7 positive cells.
Fabp7 and Fabp5 were often co-expressed in the same cells (data
not shown). (F) Schematic illustration of the expression patterns of
Fabp7 and Fabp5. Fabp7 and Fabp5 positive cells have neural
stem/progenitor cell like properties, and that the former showed
slightly more primitive characteristics than the latter.
Found at: doi:10.1371/journal.pone.0005085.s004 (9.61 MB TIF)
Figure S5 Transition of PUFAs into the brains of rat pups. The
ratio of ARA/DHA in the hippocampus of ARA(+) diet-treated rat
pups is higher, and conversely lower in DHA(+) diet-treated pups,
compared to that of control diet-treated rats. Because pups are
totally dependent on maternal breast milk of their mothers would
have ingested PUFAs and secreted them into their milk, pups can
take ARA or DHA from breast milk at the early postnatal stage.
After 3 weeks, pups also eat the food containing PUFAs by
themselves. Therefore, PUFAs are thought to be continuously
transferred to the brain of pups until P31. Scheffe’s F test was
performed and error bars show mean6SE.
Found at: doi:10.1371/journal.pone.0005085.s005 (0.66 MB TIF)
Figure S6 Identification of neural progenitor cells in the DG of
ARA(+) diet-treated wild-type rats. (A) Experimental design for
ARA(+) diet-diet-treatment. Rat pups and their mothers are fed
with two different diets [control or ARA(+)] from P2 to P31. They
were sacrificed at P31. (B) The number of PSA-NCAM positive
cells was increased in the DG of the ARA(+) diet-treated wild-type
rats compared to control diet-treated rats.
Found at: doi:10.1371/journal.pone.0005085.s006 (4.55 MB TIF)
Figure S7 Cell fate analysis of newborn cells in the DG of
PUFA-treated rats. (A) Experimental design for survival and cell
fate assays in the PUFA- treated rats. The PUFA-treated rats were
injected with BrdU three times at P30 and sacrificed at P31 or
P37. (B) Calculated survival rate and differentiation rate of BrdU-
positive cells in the DG 7 days after BrdU-injection at P30. The
survival rate was not differed between control diet-treated wild-
type rats (131%) and ARA(+) diet-treated wild-type rats (132%)
(see the fourth column), while it was reduced in DHA(+) diet-
treated wild-type rats (114%) and to lesser extent in ARA(+)-
DHA(+) diet-treated rats (123%), compared with control diet
treated wild-type rats. The percentage of NeuN positive cells in
total BrdU positive cells corresponds to the degree of production of
newborn neurons. The frequency of NeuN positivity in total
BrdU+ cells was lower in ARA(+) diet-treated wild-type rats (51%)
but higher in DHA(+) diet-treated wild-type rats (66%) compared
with control diet treated wild-type rats (see the fifth column). (C) A
BrdU labeled cell expressing NeuN at 7 days after BrdU injection
in a control diet-treated wild-type rat. (D) Estimated numbers of
newborn neurons that were double positive for BrdU and NeuN,
were calculated using the survival rate and the differentiation rate
(=the third column value6the fifth column value in B). The
estimated total number of newly generated neurons of ARA(+)
diet-treated rats examined at P37 showed a trend of increase,
although statistically not significant, compared to those from the
control diet-treated rats. Although the DHA(+) diet-treated rats
showed a comparable increase of newly generated neurons to that
of the ARA(+) diet-treated rats, this increase is thought to be due
to the accelerated differentiation to NeuN positive cells. That is, a
relatively high ratio of (NeuN+)&(BrdU+)/total BrdU+ cells (the
fifth column in B) indicates that DHA promotes neuronal
differentiation rather than production of progenitor cells. In
addition, the relatively low ratio of P37/P31 BrdU+ cells (114%)
(the fourth column in B) in the DHA(+) diet-treated rats is
consistent with the above theory, because later lineages of
progenitor cells have a more limited number of cell divisions.
The number of newly generated neurons in ARA(+)DHA(+) diet-
treated rats was not changed compared with that of control diet-
treated rats. This might suggest that ARA and DHA impinge on
the generation of new neurons in an antagonistic manner.
Found at: doi:10.1371/journal.pone.0005085.s007 (1.06 MB TIF)
Figure S8 Effects of ARA(+) diets on PPI in Pax6(+/2) rats. (A),
Experimental design of the analyses. (B), PPI was scored at pp71.
Fatty Acid, Neurogenesis, PPI
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but similar trends were observed as those in Figure 4C. Scheffe’s F
test was performed and error bars show mean6SE.
Found at: doi:10.1371/journal.pone.0005085.s008 (0.87 MB TIF)
Text S1 Materials and Methods for supporting information
Found at: doi:10.1371/journal.pone.0005085.s009 (0.02 MB
DOC)
Table S1 List of primary and secondary antibodies used in the
current study.
Found at: doi:10.1371/journal.pone.0005085.s010 (0.02 MB
XLS)
Table S2 Summary of relationship between postnatal neuro-
genesis and PPI shown in this study.
Found at: doi:10.1371/journal.pone.0005085.s011 (0.01 MB
XLS)
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